Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METROCREAM vs METROGEL-VAGINAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
Rosacea (inflammatory papules and pustules),Topical treatment of bacterial vaginosis (off-label)
Treatment of bacterial vaginosis (FDA-approved),Off-label: Trichomoniasis, anaerobic bacterial infections
Topical, apply a thin film to affected area once or twice daily.
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
Hepatic metabolism via oxidation and glucuronidation. Metronidazole is metabolized by CYP450 enzymes, primarily CYP2A6 and CYP3A4, forming metabolites such as hydroxy metronidazole and acetic acid metabolite.
Hepatic metabolism via oxidation and glucuronidation; major metabolite: hydroxy-metronidazole (active).
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Renal: 60-80% unchanged; fecal/biliary: 6-15%
Metronidazole: <20% bound to plasma proteins.
<20% bound; primarily to serum albumin (minimal binding)
Vd: ~0.6-0.7 L/kg, indicating distribution into total body water.
0.25-0.85 L/kg (widely distributed to tissues, including vaginal mucosa and cerebrospinal fluid)
Topical: Systemic bioavailability approximately 0.1-1% of applied dose for metronidazole 1% cream.
Intravaginal: Systemic bioavailability approximately 50-60% relative to oral; vaginal absorption variable (mean ~56% of oral dose)
No adjustment required for topical application.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min); use with caution.
No adjustment required for topical application.
No specific Child-Pugh based adjustments available. Use with caution in severe hepatic impairment due to potential metronidazole accumulation.
Safety and efficacy not established in pediatric patients under 18 years.
Safety and efficacy not established in pediatric patients; data insufficient for weight-based dosing.
No specific dose adjustment recommended; use caution due to potential skin atrophy.
No specific dose adjustment required. Use standard dosing with consideration of age-related decline in renal function and potential for concurrent medications.
None
No FDA boxed warning.
Avoid contact with eyes. Use with caution in patients with blood dyscrasias or history of hypersensitivity to metronidazole. Prolonged use may result in overgrowth of non-susceptible organisms. Discontinue if irritation occurs.
Carcinogenicity: Avoid unnecessary prolonged use; rodent studies showed tumorigenicity.,Peripheral neuropathy: May occur with high doses or prolonged therapy.,Candidiasis: May overgrow Candida; treat concurrent infections.,Neutropenia: Monitor CBC if retreatment needed.,Alcohol interaction: Disulfiram-like reaction (abdominal cramps, nausea, vomiting) if alcohol consumed within 48 hours.,Hepatic impairment: Use with caution; dose adjustment may be needed.
Hypersensitivity to metronidazole or any component of the formulation.
Hypersensitivity to metronidazole or nitroimidazoles,Pregnancy: Contraindicated in first trimester (use only if clearly needed in second/third trimester),Use with alcohol or propylene glycol,Use with disulfiram (within 2 weeks)
No significant food interactions due to negligible systemic absorption. However, alcohol consumption should be avoided during treatment and for at least 48 hours after discontinuing metronidazole, as trace systemic absorption may cause disulfiram-like reactions (nausea, vomiting, flushing, headache).
Avoid alcohol and any products containing alcohol (e.g., certain sauces, vinegars, desserts, mouthwashes) during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions.
Topical metronidazole (Metro Cream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, data do not suggest an increased risk of major malformations; however, use in first trimester is generally avoided due to theoretical risk. For topical application, systemic absorption is minimal (approximately 2%), and the drug is considered safe throughout pregnancy, with no known fetal risks.
Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations, but some studies suggest a possible association with cleft lip/palate; use only if clearly needed. In the second and third trimesters, no increased risk of fetal abnormalities has been reported. Avoid use in preterm labor or premature rupture of membranes due to potential systemic absorption.
Minimal systemic absorption of metronidazole after topical application (approximately 2%) results in negligible transfer into breast milk. M/P ratio is not established for topical route. Use during breastfeeding is considered compatible; however, avoid application to breast area to prevent infant exposure.
Metronidazole is excreted in breast milk; after vaginal administration, systemic absorption is minimal (approximately 2% of oral dose), resulting in low milk concentrations. The M/P ratio is approximately 0.8-1.0 for oral dosing; for vaginal gel, ratio is expected lower. The American Academy of Pediatrics considers single-dose therapy compatible with breastfeeding after timed dosing and discarding milk for 12-24 hours. For chronic use, monitor infant for gastrointestinal disturbances.
No dosage adjustment is necessary during pregnancy. Systemic absorption from topical application is minimal and pharmacokinetic changes in pregnancy do not warrant dose modification.
No dose adjustment is required for METROGEL-VAGINAL during pregnancy. Systemic absorption is low (<2%), and pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) do not necessitate dose modification for vaginal administration. Use standard dosage: one applicatorful (5 g containing 37.5 mg metronidazole) intravaginally once or twice daily for 5 days.
Metronidazole topical cream is contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Avoid contact with eyes, mucous membranes, or open wounds. Use during pregnancy only if clearly needed (FDA category B). Warn patients that topical metronidazole may cause transient skin irritation or dryness; if severe, discontinue use. Combine with sunscreen and photoprotective measures due to potential photosensitivity. For rosacea, clinical improvement may take 3–4 weeks; adherence is critical. Do not use with concomitant oral metronidazole or disulfiram-like reactions due to minimal systemic absorption.
Metronidazole vaginal gel is first-line for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Use caution in patients with Cockayne syndrome due to risk of severe hepatotoxicity. May cause metallic taste. Do not use during menstruation; treatment is typically 5 days but can be extended to 7-10 days for recurrent BV.
Apply a thin layer to affected areas once or twice daily as directed.,Wash hands before and after application; avoid contact with eyes, mouth, and nostrils.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,May cause mild stinging, burning, or dryness; if severe, stop use and inform your physician.,Minimize sun exposure and use sunscreen daily as metronidazole may increase sun sensitivity.,Notify your doctor if you develop signs of allergic reaction: rash, itching, swelling, or trouble breathing.,Do not use more than prescribed; extended use may lead to bacterial resistance.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using.,Inform your doctor if you are taking oral metronidazole or have a history of blood disorders or neuropathy.
Use the applicator to insert the gel into the vagina as directed, usually once or twice daily for 5 days.,Do not drink alcohol or use alcohol-containing products (mouthwash, cough syrup) during treatment and for 2 days after stopping.,You may notice a metallic taste in your mouth, which is common and harmless.,Avoid sexual intercourse or use condoms during treatment to prevent irritation and reinfection.,Wash hands before and after use. Do not use tampons, douches, or other vaginal products during therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METROCREAM vs METROGEL-VAGINAL, answered by our medical review team.
METROCREAM is a Antibiotic (Nitroimidazole) that works by Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.. METROGEL-VAGINAL is a Antibiotic (Nitroimidazole) that works by Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METROCREAM and METROGEL-VAGINAL depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METROCREAM is: Topical, apply a thin film to affected area once or twice daily.. The standard adult dose of METROGEL-VAGINAL is: One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METROCREAM and METROGEL-VAGINAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METROCREAM is classified as Category C. Topical metronidazole (MetroCream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, da. METROGEL-VAGINAL is classified as Category C. Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.